The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

(2017) Pasi A. Jänne et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Trametinib Drives T-cell–Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis

(2016) Michael J. Allegrezza et al.   CANCER RESEARCH

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells

(2016) E. J. Brea et al.   Cancer Immunology Research

M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment

(2015) E. Van Overmeire et al.   CANCER RESEARCH

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

(2015) Stefano Ugel et al.   JOURNAL OF CLINICAL INVESTIGATION

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Macrophages and cancer: from mechanisms to therapeutic implications

(2015) Renato Ostuni et al.   TRENDS IN IMMUNOLOGY

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

(2014) John C Castle et al.   BMC GENOMICS

The Erk2 MAPK Regulates CD8 T Cell Proliferation and Survival

(2014) W. N. D'Souza et al.   JOURNAL OF IMMUNOLOGY

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

The Monocyte to Macrophage Transition in the Murine Sterile Wound

(2014) Meredith J. Crane et al.   PLoS One

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response

(2014) P. Kvistborg et al.   Science Translational Medicine

MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells

(2014) L. J. Vella et al.   Cancer Immunology Research

Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage Population

(2013) D. Laoui et al.   CANCER RESEARCH

The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer

(2013) K. Mimura et al.   JOURNAL OF IMMUNOLOGY

Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells

(2013) Robert L. Kortum et al.   TRENDS IN IMMUNOLOGY

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

(2011) Marie Tosolini et al.   CANCER RESEARCH

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

(2008) Paulo C. Rodríguez et al.   IMMUNOLOGICAL REVIEWS